Advances in Treatment of Progressive Multifocal Leukoencephalopathy

Raphaël Bernard-Valnet; Igor J. Koralnik; Renaud Du Pasquier

doi:10.1002/ana.26198

Advances in Treatment of Progressive Multifocal Leukoencephalopathy

Raphaël Bernard-Valnet^*, Igor J. Koralnik, Renaud Du Pasquier

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Progressive multifocal encephalopathy (PML) is a severe demyelinating disease of the central nervous system (CNS) caused by JC virus (JCV), which occurs in immunocompromised individuals. Management of PML relies on restoration of immunity within the CNS. However, when this restoration cannot be readily achieved, PML has a grim prognosis. Innovative strategies have shown promise in promoting anti-JCV immune responses, and include T-cell adoptive transfer or immune checkpoint inhibitor therapies. Conversely, management of immune reconstitution inflammatory syndrome, particularly in iatrogenic PML, remains a major challenge. In this paper, we review recent development in the treatment of PML. ANN NEUROL 2021;90:865–873.

Original language	English (US)
Pages (from-to)	865-873
Number of pages	9
Journal	Annals of neurology
Volume	90
Issue number	6
DOIs	https://doi.org/10.1002/ana.26198
State	Published - Dec 2021

ASJC Scopus subject areas

Clinical Neurology
Neurology

Access to Document

10.1002/ana.26198

Cite this

@article{459621c4d857444eb8d25c4c9263daee,

title = "Advances in Treatment of Progressive Multifocal Leukoencephalopathy",

abstract = "Progressive multifocal encephalopathy (PML) is a severe demyelinating disease of the central nervous system (CNS) caused by JC virus (JCV), which occurs in immunocompromised individuals. Management of PML relies on restoration of immunity within the CNS. However, when this restoration cannot be readily achieved, PML has a grim prognosis. Innovative strategies have shown promise in promoting anti-JCV immune responses, and include T-cell adoptive transfer or immune checkpoint inhibitor therapies. Conversely, management of immune reconstitution inflammatory syndrome, particularly in iatrogenic PML, remains a major challenge. In this paper, we review recent development in the treatment of PML. ANN NEUROL 2021;90:865–873.",

author = "Rapha{\"e}l Bernard-Valnet and Koralnik, {Igor J.} and {Du Pasquier}, Renaud",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.",

year = "2021",

month = dec,

doi = "10.1002/ana.26198",

language = "English (US)",

volume = "90",

pages = "865--873",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Advances in Treatment of Progressive Multifocal Leukoencephalopathy

AU - Bernard-Valnet, Raphaël

AU - Koralnik, Igor J.

AU - Du Pasquier, Renaud

PY - 2021/12

Y1 - 2021/12

N2 - Progressive multifocal encephalopathy (PML) is a severe demyelinating disease of the central nervous system (CNS) caused by JC virus (JCV), which occurs in immunocompromised individuals. Management of PML relies on restoration of immunity within the CNS. However, when this restoration cannot be readily achieved, PML has a grim prognosis. Innovative strategies have shown promise in promoting anti-JCV immune responses, and include T-cell adoptive transfer or immune checkpoint inhibitor therapies. Conversely, management of immune reconstitution inflammatory syndrome, particularly in iatrogenic PML, remains a major challenge. In this paper, we review recent development in the treatment of PML. ANN NEUROL 2021;90:865–873.

AB - Progressive multifocal encephalopathy (PML) is a severe demyelinating disease of the central nervous system (CNS) caused by JC virus (JCV), which occurs in immunocompromised individuals. Management of PML relies on restoration of immunity within the CNS. However, when this restoration cannot be readily achieved, PML has a grim prognosis. Innovative strategies have shown promise in promoting anti-JCV immune responses, and include T-cell adoptive transfer or immune checkpoint inhibitor therapies. Conversely, management of immune reconstitution inflammatory syndrome, particularly in iatrogenic PML, remains a major challenge. In this paper, we review recent development in the treatment of PML. ANN NEUROL 2021;90:865–873.

UR - http://www.scopus.com/inward/record.url?scp=85114317515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114317515&partnerID=8YFLogxK

U2 - 10.1002/ana.26198

DO - 10.1002/ana.26198

M3 - Review article

C2 - 34405435

AN - SCOPUS:85114317515

SN - 0364-5134

VL - 90

SP - 865

EP - 873

JO - Annals of Neurology

JF - Annals of Neurology

IS - 6

ER -

Advances in Treatment of Progressive Multifocal Leukoencephalopathy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this